Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00668304 · ClinicalTrials.gov registry record · Phase 4

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

A Phase 4 study, sponsored by Bayer.

Completed
Registry status
Phase 4
Development phase
192
Enrollment target

NCT00668304: Completed Phase 4 study, sponsored by Bayer.

NCT00668304 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 192 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00668304, a Phase 4 study, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 4
Development phase
192 participants
Enrollment target

Study Summary

This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.

Interventions

  • DRUG Avelox (Moxifloxacin, BAY12-8039)

Trial Details

FieldValue
Enrollment Target 192 participants
Start Date 2004-06
Est. Completion 2005-01
Phase Phase 4
Bayer

591 total trials

What the finished NCT00668304 record still lists

NCT00668304 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 1 intervention - of which Avelox (Moxifloxacin, BAY12-8039) is the first listed.

NCT00668304 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00668304 about?

NCT00668304 is a clinical study titled "Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox". This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.

What is the current status of trial NCT00668304?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 192 participants. The study started on 2004-06. Estimated completion is 2005-01.

What interventions are being tested in trial NCT00668304?

The interventions under investigation include: Avelox (Moxifloxacin, BAY12-8039) (DRUG).

Who is sponsoring clinical trial NCT00668304?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00668304's enrollment target sits among peer trials

192 451st of 2000 higher than 1,548 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492972 · 192 participants · Phase 3

    Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

  • NCT01973881 · 192 participants

    Quantitative MRI for Myelofibrosis

  • NCT02535702 · 192 participants · NA

    Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

  • NCT03622359 · 192 participants · NA

    Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00668304, the US trial registry maintained by the National Library of Medicine. NCT00668304 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.